NL-OMON35295已完成不适用
An open label, single center study to investigate the metabolic profile of dalcetrapib after a single oral dose in healthy male subjects - Dalcetrapib ADME study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- healthy male subjects
- •- 45-65 yrs, inclusive
- •- BMI:18-32 kg/m2, inclusive
- •- non-smoker or moderate smoker (* 5 cigarettes per day)
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
Single-Center, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-radio-labeled RO4602522 in Healthy Male Volunteers10029305Alzheimer's diseasedementiaNL-OMON36882Hoffmann-La Roche6
已完成
不适用
Single center, open-label study investigating the excretion balance, pharmacokinetics and metabolism of a single oral dose of [14C]-labeled RO6889450 in healthy male volunteers10039628SchizophreniaNL-OMON51079F. Hoffman-La Roche Ltd6
已完成
不适用
Single-center, open-label exploratory study to assess the efficacy and safety of TSUMURA Kamikihito Extract Granules for Ethical Use (TJ-137) for the treatment of anxiety in patients with chronic constipation syndromeChronic constipation syndromeJPRN-UMIN000026244Kobayashi Medical Clinic Tokyo25
已完成
不适用
A single-center, open-label study to investigate the absorption, distribution, metabolism and excretion (ADME) of LEE011 after a single oral dose of 600 mg [14C]LEE011 (0.37 MBq) in healthy male subjectsgevorderde kankeradvance cancerNL-OMON40904ovartis6
已完成
不适用
A single-center, open-label study to investigate the absorption, distribution, metabolism and excretion (ADME) of HDM201 (Siremadlin) after a single oral dose of 25 mg [14C]HDM201 in healthy subjects10027656CancerNL-OMON49451ovartis Pharma AG5